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Background
In Burundi Triomune® is the first-line HIV treatment
and it is estimated to reach 30% of those in need, but
efficacy monitoring does not rely on viral load (VL)
quantification, due to cost and technical limitations.
F u r t h e r m o r en e v i r a p i n e( N V P )i sk n o w nt oh a v ea
highly variable pharmacokinetics (PK) and pharmacoge-
netics (PG), but no data are currently available in this
population.
Purpose of the study
To study virological outcome, PK and PG of nevirapine-
based HAART in Burundi, by relying on previously
validated alternative tools for samples collection.
Materials and methods
A cross-sectional analysis was performed at the rural hos-
pital of Kiremba, northern Burundi. All patients on
HAART (>6 months) presenting for care and willing to
participate were enrolled. After sample collection, whole
blood (50 µL) was spotted on Whatman 903 Cards (Dried
Blood Spot, DBS); afterwards plasma (100 µL, after centri-
fugation) was spotted on glass paper filter (dried plasma
spots, DPS). DBS were used for VL testing (NucliSENS
EasyQ HIV-1 v2.0) and PG analysis (516G>T and 983C>T
SNPs in CYP2B6, 3435C>T and 1236 C>T in MDR1).
A validated HPLC method was used to measure NNRTIs
concentrations on DPS.
Results
239 patients (68.2% female) were enrolled; mean (±SD)
age and BMI were respectively 37.9 years (±10) and
20.7 Kg/m
2 (±2.8). The majority of them (90.8%) were
in WHO stage 3 and last CD4+ cell count was 543
cell/mm
3 (±345). 237 were on first line treatment (220
on NVP and 17 on EFV) and 2 (0.8%) on second line
(LPV/r). Mean time on treatment was 25.7 months
(±13.7) and it correlated to the last CD4+ count (Pear-
son 0.23, p=0.001). 43 (18%) had a detectable viral load
with 14 patients (5.8%) having more than 800 copies/
ml. Nevirapine and efavirenz Ctrough were 7727 ng/ml
(± 3796) and 4027 ng/ml (± 3041). CYP2B6 mutated
S N P sw e r ec o m m o n( 4 8 , 5 %i n5 1 6 G > T ,1 3 , 6 %i n
983C>T) and associated to increasing exposure (p=0.01
and p=0.02). A higher proportion of patients (95.6% vs.
88.5%, p>0.05) had viral loads below 800 copies/ml in
the higher range of NVP concentration (Ctrough
>4300 ng/ml).
Conclusions
DPS and DBS showed to be useful tools to collect and
transport samples from a rural area of Burundi. Even
with the limit of a cross-sectional analysis a high effec-
tiveness was noted, showing 82% of patients with unde-
tectable VL at a mean of 2 years since start of
treatment. High NVP plasma concentrations along with
favorable genetic profile could partially explain these
results.
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